GSK/Novartis Support For Benefiber Claims Too Thin To Convince NARB
This article was originally published in The Tan Sheet
Referring to rather than providing two studies was GSK/Novartis' downfall in arguing before the National Advertising Review Board to support Benefiber regularity claims. GSK/Novartis questions the panel’s "refusal to accept the full translations of two confirmatory studies referred to in the record."
You may also be interested in...
Two months after referring advertising for its Hair Volume supplement to FTC, NAD zeroes in on claims for New Nordic USA's Skin Care Collagen Filler supplement. NAD says the firm should discontinue anti-wrinkle and collagen-building claims in the absence of reliable evidence from well-controlled human clinical testing.
Latest warnings also include second and third businesses in US cannabidiol and hemp sector found making unlawful claims for treating and preventing COVID-19. Four of five firms warned apparently responded by removing violative claims from websites and social media posts.
OTC Decisions In March: Lumify Single-Use, Aleve Arthritis-Grip Cap Labeling, And More Prilosec, Mucinex Copies
Total of CDER decisions during March on OTC applications was down from January and February and also were less substantial for the marketplace. After approving OTC switches in first two months, March decisions for newly available OTCs were limited to additional guaifenesin/pseudoephedrine and omeprazole products offered as private label/store brand alternatives to brands.